Clinical Trials Browser

Phase 2 × Colorectal Cancer Metastatic × ARQ 197 × Clear all

NCT01892527 2022-09-09

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Phase 2 Completed

Gastrointestinal

Colorectal Cancer Metastatic